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Introduction: Identification of metastatic miRNAs and understanding their 
complex functions provides prognostic and diagnostic bio markers In this 
study, the expression of miR-372, fgf-9 gene, miR-137 and cdc42 gene was 
evaluated in the serum of patients with lung cancer. 
Materials and Methods: In the present study, 50 serum samples were 
collected from healthy individuals and 50 serum samples from people with 
NSCLC from Masih Daneshvari Hospital in Tehran. Clinicopathological 
information was collected through questionnaires. 
In the molecular study, changes in expression of miR-372, miR-137, fgf-9 and 
cdc42 genes in healthy individuals and those with lung cancer were evaluated 
using Real Time PCR. 
Results: Expression of miR-372, fgf-9 and cdc42 genes in the first to third 
stage serum of metastases and expression of miR-137 in serum of the first and 
second stages of the disease were not significantly different from the normal 
one. However, in the serum of the fourth stage of the disease, expression of 
miR-372 and cdc42 gene were significantly increased by 7.3 and 3.4 folds than 
normal subjects, while in the serum of the fourth stage of the disease, the 
expression of fgf-9 gene was significantly reduced by 4.46 fold .The 
expression of miR-137 in the serum of the third and fourth stages of the 
disease was significantly reduced by 3.2 and 6.8 fold compared to the normal 
serum 
Conclusion: It is likely that the expression of miR-372, miR-137, fgf-9 and 
cdc42 genes in human serum could be used to predict the stage of lung cancer 
metastasis. 
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     Lung cancer is characterized by high 
genetic variation and with the lowest 
number of recurrent mutations which occurs 
with great frequency [1]. The number of 
newly diagnosed lung cancer cases and the 
number of deaths worldwide are responsible 
for 12.9% of all detected cancers and 19.4% 
of all deaths from cancer [2]. Lung cancer is 
one of the most common cancers and the 
second leading cause of cancer deaths in 
Iran. The five-year incidence of lung cancer 
in Iran was 5.38 per 100,000 people [3]. 
Smoking is a major risk factor for lung 
cancer. Smoking causes at least 80% 
mortality from lung cancer [4]. 
Histologically speaking, 85% of lung 
cancers are Non-Small Cell Lung Cancers 
(NSCLCs) and 15% of lung cancers are 
Small Cell Lung Cancers (SCLCs) [3]. 
NSCLCs are divided into subgroups such as 
lung adenocarcinoma (about 40%), 
squamous cell carcinoma (25-30%), and 
large cell carcinoma (10-5%). Therefore, 
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the most common type of lung cancer is 
adenocarcinoma [4]. 
MicroRNAs (miRNAs) are small RNAs 
(20-22 nucleotides), non-coding and 
intragenic and controls a large range of 
biological processes that include apoptosis, 
evolution, proliferation and differentiation 
[3, 5]. Additive or decreasing changes in 
some of the miRNAs that lead to the 
cancerous process, affect cell growth by 
interfering with cell cycle regulators. 
MiRNAs play a key role in the tumor 
process and control the death of tumor cells 
in a programmed manner. Through altering 
their function, the survival of cancer cells 
can be regulated [6]. 
MicroRNA-372 is located on region 13 of 
the long arm of chromosome 19 (19q13.42) 
and is a member of the miR-371-372 gene 
family. The miR-372 promotes cellular 
proliferation, cell cycle, and apoptosis in the 
tumors of the testicular germ cells, as well 
as lines of gastric cancer cells. MiR-372 is a 
prognostic marker for predicting cancer 
recurrence and survival in patients with 
non-small cell lung cancer, independent of 
the stage or type of tissue [7].  
The gene encoding MicroRNA-137 (miR-
137) is located on the chromosome 1p22. In 
colorectal cancer, the miR-137 induces 
cellular G1 blockage and inhibition of 
invasion through targeting Cell Division 
Cycle 42 (CDC42). In the adrenocarcinoma 
of the lung, the expression of miR-137 has 
decreased by more than 20 times in 
comparison with the normal lung tissue [8]. 
Fibroblast growth factor 9 (fgf-9) is one of 
the family members of the fibroblast growth 
factor (fgf) family that modulates 
proliferation, differentiation and cellular 
mobility [9]. The fgf-9 gene is located on 
the long arm of chromosome 13 (13q12.11) 
[10]. The fgf family has important 
implications for fetal growth, tissue repair, 
and tumorigenicity. The activation of fgf 
signals, including fgf-9 is associated with 
the pathogenesis of several cancers. Fgf-9 is 
expressed in patients with lung 
adenocarcinoma and the change in the 
function of fgf-9 reduces the development 
and progression of lung adenocarcinoma. 
The findings indicate that the overall 
survival time was considerably shorter in 
patients with a high expression of fgf-9 
compared to patients with low expression of 
fgf-9. The expression of fgf-9 protein was 
associated with the disease stage and 
metastasis of the lymph node in patients 
with lung adenocarcinoma [9]. 
CDC42 is a member of the Rho GTPase 
family and acts as an important molecular 
switch [11]. The CDC42 gene is located on 
the short arm of chromosome 1 (1p36.12) 
[12]. 
Cdc42 is mainly involved in the formation 
of actin, cellular migration, migration and 
cell growth. The researchers found that 
Cdc42 was over-expressed in several types 
of human cancers; the excessive expression 
of Cdc42 was linked to carcinogenesis and 
the progression of many human tumors. The 
findings showed that Cdc42 was 
overexpressed in patients with primary lung 
cancer [11].  
MiR-372 binds directly to its target gene, 
the fgf-9 gene. MiR-372 enhances 
proliferation and invasion of lung squamous 
cells by inhibiting fgf-9. Fgf-9 is highly 
expressed in patients with lung 
adenocarcinoma, and this aberrant 
expression of fgf-9 may inhibit lung 
adenocarcinoma progression. [13] 
Decreased expression of Cdc42, Cdk6, 
cyclin D1, p-ERK1/2 and p-Rb occurs due 
to increased miR-137 expression. miR-137 
is involved in the carcinogenesis of lung 
cells by inhibiting the expression of two 
Cdc42 and Cdk6 genes. [14] 
NSCLC is the leading cause of death from 
cancer worldwide, and the overall 5-year 
survival rate for lung cancer is only about 
10-15%. The main reason for this low five-
year survival is that the disease is diagnosed 
in three quarters of the patients late, so the 
disease progresses and surgery is not 
possible. In the past 10 years, research on 
prognostic and prognostic bio markers has 
shown improvements in the early screening 
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of lung cancer. Therefore, considering the 
availability and recognition of the 
expression of miRNAs and genes in serum 
samples in numerous studies, and because, 
the serum is useful for biomarker-related 
studies, in this study, expression of miR-
372, fgf-9 gene, miR-137 and cdc42 gene 
was evaluated in the serum of patients with 
lung cancer. 
 
2. Materials and Methods 
      The present study was descriptive-
analytic and random sampling was 
performed. After obtaining satisfaction from 
the patients, the expression of miR-372, fgf-
9, miR-137 and cdc42 gene in the serum of 
healthy individuals and people with lung 
cancer was quantitatively evaluated. The 
sample consisted of 50 serum samples of 
healthy subjects and 50 serum samples of 
patients with NSCLC that were collected 
from Masih Daneshvari Hospital in Tehran. 
Patient samples were collected from people 
who were in the first to fourth stage of 
cancer. 
 
2.1 Questionnaire Design 
     To record personal and clinicopathologic 
data, first, consent was obtained from 
people to enter this study, and then a 
questionnaire was designed. In the 
questionnaire, the patient's information 
included the name, date of referral, age, sex, 
occupation, smoking (type and duration), 
duration of the disease, location, type of 
tumor, tumor stage, family history of the 
patient, history of other illness, primary 
tumor and the tumor after treatment was 
collected. 
 
2.2 Blood Sampling 
     Blood samples were taken from patients 




2.3 Isolation of the Plasma 
     Given the need for plasma to measure 
MicroRNA, blood plasma was isolated by 
refrigerating centrifuge (HANIL-South 
Korea) at 4 ° C for 15 minutes at a radius of 
1900 rpm and deposited in free RNase free 
microbes. They were kept at 80 ° C (JAL-
Iran) freezer until the tests were carried out. 
 
2.4 Extraction of miRNA from Plasma 
     To detect gene expression, miRNA 
should be extracted from the plasma. The 
RNA was extracted using a Qiagen-
Germany extraction kit, according to the kit 
protocol. 
 
2.5 Quantitative and Qualitative 
Research of the Extracted RNA  
     After the extraction of RNA through 
spectrophotometry (USA, Thermofisher) 
and agarose gel electrophoresis (Iran-
Padideh Nojen pars), its quantity and 
quality was investigated. 
 
2.6 Stages of Agarose Gel 
Electrophoresis 
     First, 0.25 g of agarose powder 
(Germany -MERCK) was weighed and with 
heat was dissolved in a volume of 25 ml of 
Tris-Acetate-EDTA 1X (TAE 1X) buffer.  
The gel was transferred to the 
electrophoresis container and the shoulder 
was inserted into it. Then the TAE 1X 
buffer was added. The resulting mixture of 
RNA extraction was transferred to the well 
and a voltage of 0-1 volts per 1 cm length of 
gel was established between (91 - 111 
volts). Finally, a gel doc device (gel 
documentation system) was used to view 
the gel (Germany -NANOLYTIC). 
 
2.7 Preparing RNA Template 
     The Poly A polymerase enzyme adds to 
the end of the nucleotide sequence of 
miRNA, the poly A tail, and makes the 
sequence longer and more stable. To 
prepare the RNA template, 200 ng of 
miRNA was mixed with 0.5 μl of enzyme, 1 
μl of ATP, 1 μl of buffer, and placed in 
thermocycler (China-BIOEREE) for 30 
minutes at 37 ° C.  
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2.8 Synthesis of cDNA 
     Following preparation of the RNA 
template, the next steps were performed for 
complementary DNA (cDNA) synthesis 
using the cDNA synthesis kit (Thermo 
Scientific): 
5 µl of RNA Template (100 ng constant for 
each sample) was added to a new 0.2 µl 
microtube; then, 7 µl of water and gene-
specific primer were added to all samples. 
The specimens were placed in a 
thermocycler for 5 min at 65 ° C (70 Lid). 
Subsequently, the samples were removed 
from the thermocycler and μl2 dNTP, 4 μl 
reaction buffer, 1 μl RT and 1 μl RNAase 
inhibitor were added to each sample. The 
specimens were placed in a thermocycler 
according to schedule (42 ◦C (60 min), and 
Lid 45 ◦C). 
 
2.9 Primers’  Design 
     The primers used were designed by 
means of the NCBI site and the Allele ID 
software. The sequence of primers is shown 
in Table 1. 
 




fgf-9 F 5’- CTTTGGCTTAGAATATCCTTA -3’ 132 bp 
fgf-9 R 5’- AGTGACCACCTGGGTCAGTCC -3’ 132 bp 
U6 F 5’-GCTTCGGCAGCACATATAC-3’ 137 bp 
U6 r 5’-ATTCCGTTTCTGGGAGGG-3’ 137 bp 
miR-372 F 5’-GCCCGCAAAGTGCTGCGACAT-3’ 121 bp 
miR-372 R 5’-CCAGTGCAGGGTCCGAGGT-3’ 121 bp 
cdc42 F 5’-GATGGTGCTGTTGGTAAA-3’ 127 bp 
cdc42 R 5’-GAGTATATGGTTCTCCACC-3’ 127 bp 
miR-137 F 5’-GCGCGCTTATTGCTTAAGAATAC-3’ 112 bp 
miR-137 R 5’-GTGCAGGGTCCGAGGT-3’ 112 bp 
 
2.10 Evaluation of Primer 
Performance and Real Time PCR 
Reaction 
     The efficiency of the designed primers 
was determined and the standard curve for 
each of them was plotted. To do so, five 
dilutions were first made from cDNAs, and 
then the Real Time PCR (Polymerase chain 
reaction) (BIONEER-South Korea) was 
repeated twice for each dilution, with each 
of the primers separately. At the end, the 
standard curve for each primer was plotted 
based on the values of Ct obtained versus 
the dilutions used. Using the gradient curve 
(slope) obtained and the relationship of E= 
10
(-1/slope)
 – 1, the reaction efficiency (E) 
was calculated for each primer. 
Measurement of the expression of miR-372, 
fgf-9, miR-137 and cdc42 gene was 
repeated by propagation by Real Time PCR 
based on standard and relative methods. The 
Real Time PCR reaction was performed 
using the ExicyclerTM 96 bioneer (South 
Korea) fixed-type device and the Eva Green 
color. Samples were prepared according to 
the protocol of Kit Universal RT miRNA 
qPCR made by Exiqon-Denmark to the 
final volume of 20 μl and the replication of 
miRNAs, genes and reference gene with the 
same thermal program. Each cycle 
consisted of four incubation stages of 95 ° C 
for 5 minutes, 95 ° C for 30 seconds, 60 ° C 
for 30 seconds, and 72 ° C for 30 seconds. 
After the reaction, the expression rate was 
measured using ΔΔct method and statistical 
analysis was performed with REST 
software. 
 
2.11 Statistical Method 
2.11.1 The Studied Variables  
     Since the comparison between the 
healthy and metastatic groups was done, the 
2
-ΔΔCT
 formula (Livak formula) was used to 
calculate the differences in expression of 
miR-137, miR-372, fgf-9 and cdc42. The 
reference gene in this study was the U6 





2.11.2 Methods and Tools of Data 
Analysis 
     Data were analyzed using SPSS 22 
software and Excel. Descriptive and 
demographic variables were described using 
frequency indices, frequency percentages 
and graphs. In the inferential findings 
section and testing the hypotheses, binomial 
test was used to compare the accuracy of 
the survey method.  
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3. Results 
     Demographic and clinical data of 
patients were extracted from the 
information recorded in the electronic 
system of cancer department of the hospital. 
(Table 2) 
 





50 person person Number of patients 
20% ( 10) 51-60 Age 
46%( 23)  61-70  
30% (15)  71-80 
4% (2)  Up to 80 
35 persons 
(70%) 










Not taking  
22persons 
(44%) 




does not have  
 
3.1 The Result of Extracting RNAs 
and Examining their Quality 
     After serum isolation and extraction of 
RNA, the agarose gel electrophoresis was 
used to check the quality of the extracted 
RNAs. The presence of the 18S and 28S 
ribosomal bands associated with a number 
of samples in Figure 1 shows that the 
extracted RNAs have good quality. 
 




                        b) miR-137 and the cdc42 gene   
 
Figure 1. Agarose gel electrophoresis to evaluate the 
quality of the extracted RNA  No. 1-6: Examples, No. 
7: Marker. 
 
3.2 Examining the Quantity of 
Extracted RNAs  
     An absorbance ratio of 260 to 280 was 
calculated by a Nanodrap 
(spectrophotometer) and the concentration 
of RNA was achieved. The absorption ratio 
of 260 to 280 determines the purity of the 
extracted nucleic acid. In the present study, 
the absorption ratio from 260 to 280 was 
between 1.8 and 2 and the quality of 
extracted RNAs was confirmed. 
 Figure2. Using Nanodrap to Study Extracted RNA 
Quantity 
 
3.3 Evaluation of the efficiency of 
primers  
     In this study, using the cDNA dilatation 
method, the efficiency of primers used was 
calculated and shown in Figure 3.  
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b) The efficiency of the miR-372 specific primer: 99% 
 
c) The efficiency of the cdc42 gene specific primer: 
99% 
 
d) The efficiency of the miR-137 specific primer: 99% 
 
 
e) The efficiency of the U6 gene specific primer: 94% 
 
Figure 3. Evaluation of the efficiency of specific 
primers used for 
a) fgf-9 gene, b) miR-372, c) cdc42 gene, d) miR-137 
and e) U6 gene. 
 
According to Figure 3, the primer efficiency 
for fgf-9, miR-372, cdc42 and miR-137 
genes are 98%, 99%, 99% and 99%, 
respectively. 
 
3.4 Investigate and confirm the 
synthesis of cDNA and performing 
conventional PCR 
     The specificity of the primers used in the 
present study was confirmed using 
conventional PCR (China-BIOERE) PCR 
method. Figure 4 shows the primer 
specificity associated with a number of 
samples.  
  
Column 1: Negative control, Column 2: Marker 100 bp 
Column 3: The miR-137 PCR product, Column 4: PCR 
product for U6,  Column 5: The cdc42 PCR product.           
a) PCR product for miR-137, U6 and cdc42 genes  
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Column 1: Negative control, Column 2: Marker 100 bp 
Column 3: The miR-372 PCR product, Column 4: PCR 
product for U6, Column 5: The fgf-9 PCR product.           
b) PCR product for miR-372, U6 and fgf-9 genes  
 
Figure 4.  Conventional PCR with specific primers. 
 
The PCR product was applied on agarose 
gel. The presence of a single band for each 
gene on the gel indicated that no 
nonspecific band was present and the 
primer used was bound to the target gene. 
 
3.5 Results of Expression of miR-372, 
fgf-9, miR-137 and cdc42 Gene Using 
Real Time PCR 
     After confirming the creation of the 
cDNA and performing conventional PCR 
and observing the genes that showed primer 
specificity, from Quantitative Real-Time 
PCR (Q-RT PCR) method was used and 
expression of miRNAs and genes was 
investigated. This test was performed three 
times for each sample. REST software was 
used to analyze the results. 
 
3.6 Results of Expressing miRNAs 
and Genes Examined According to the 
Stage of Cancer 
     The expression levels of miR-372, fgf-9, 
miR-137 and cdc42 gene are shown in 
Figure 4 with respect to the cancer stage. 
 
 a) Expression of miR-372 and fgf-9 gene. 
 
 b) Expression of miR-137 and cdc42 gene. 
 
Figure 5. The expression of a) miR-372, fgf-9 gene, b) 
miR-137 and cdc42 gene according to the cancer stage. 
 
According to Diagrams 3 and 5, the 
expression of miR-372, fgf-9 gene and 
cdc42 gene in serum samples from the first 
to third stage of the disease and also, the 
expression of miR137 in serum of patients 
with first and second stage of disease were 
not significantly different from that of 
normal serum samples. However, the 
expression of miR-372 in serum samples of 
the fourth stage of the disease (metastasis 
stage) with a significant level of P <0.05 
(P=0.022) was significantly increased by 
7.3 times the normal serum samples. The 
level of expression of miR-137 in the serum 
of patients with the third and fourth stage 
(metastasis stage) of the disease with 
significant level P <0.05 (P=0.042) and P 
<0.01 (P=0.003) and had a significant 
decrease of 3.2 and 6.8, compared to the 
normal serum samples. The expression of 
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fgf-9 target gene in serum samples of the 
fourth stage of the disease (metastasis stage) 
with a significant level ((P <0.05) 
(P=0.024)), had a significant reduction of 
46.4 folds compared to normal serum 
samples. In the serum samples of the fourth 
stage of the disease, which is the phase of 
metastasis, the level of expression of cdc42 
gene was 3.4 times higher than normal 
serum samples ((P <0.05) (P=0.032)).  
 
3.7 Patient information 
     Demographic and clinical data of 
patients were extracted from the 
information recorded in the electronic 
system of cancer department of the hospital. 
Of the 50 patients with lung cancer, 35 were 
male (70%) and 15 were female (30%). Of 
these, 36 (72%) had tobacco use, and 14 
(28%) had no smoking. Of the 50 patients 
studied, in terms of having a history of 
cancer among family members, 28 patients 
(56%) had a history of cancer among family 
members were 22 patients (44%) of cancer 
in the family had . another remarkable point 
is that of these, 23 (46%) were in the range 
of 61-70 years of age, suggesting lung 
cancer is more likely to be aging.  
 
4. Discussion  
     Changes that lead to lung cancer include 
growth signals, insensitivity to growth 
inhibitory signals and escape from 
apoptosis, unlimited reproduction power, 
angiogenesis, tissue invasion and metastasis 
[15]. Lung cancer is responsible for more 
deaths than breast cancer and clones and 
prostate cancer [5].  
Studies have confirmed the steady presence 
of miRNAs in human body fluids including 
sputum, urine, milk, cerebrospinal fluid, 
semen, and serum and plasma. Use of 
extracellular miRNAs in body fluids is less 
invasive compared to tumor tissue biopsy.  
Since the present study aimed  to reach the 
diagnostic goal, in the serum of people with 
cancer, where microRNAs, as well as genes 
have been altered (reduced or increased), 
early diagnosis of cancer can be of great 
help in the future of the disease. 
Using real time PCR, the expression of 
miR-372, the target gene fgf-9, miR-137 
and the target gene of cdc42 were 
evaluated. 
Studies have shown that miR-372-3p was 
found significantly overexpressed in both 
lung squamous cell carcinoma (LSCC) 
tissues and cell lines, whereas FGF9 mRNA 
was found underexpressed in LSCC tissues.  
The decrease in FGF9 gene expression is 
due to the binding of MiR-372-3p to the 
3′UTR mRNA portion of the FGF9 gene. 
3′UTR is the untranslated region of the 
FGF9 gene. Decreased miR-372 expression 
increases FGF9 gene expression in LSCC 
and decreases invasion and mitosis and 
cancer cell growth in LSCC. Inhibition of 
FGF9 gene expression by miR-372 
increases the proliferation of cancer cells 
and also increases their invasive property in 
LSCC.[13] In the present study, miR-372(P 
<0.05 (P=0.022)) directly binds to fgf-9 (P 
<0.05 (P=0.024)) 3'UTR and thus reduces 
the expression of fgf-9 and increases the 
process of metastasis. 
Expression levels of miR-137 in NSCLC 
cell lines or tissue were significantly lower 
than in a normal human lung cell line or 
adjacent normal tissues. The data also show 
that upregulation of miR-137 inhibited the 
proliferation of NSCLC cells, whereas 
silencing of miR-137 promoted the 
proliferation of NSCLC. In addition, 
Transforming Growth Factor Alpha 
(TGFA) has been identified as a direct 
target gene of miR-137 in NSCLC cells. 
Finally, knockdown of TGFA led to the 
suppression of NSCLC cell proliferation. 
Overall, findings indicated that miR-137 
served as a tumor suppressor in NSCLC and 
its suppressive effect is mediated by 
repressing TGFA expression [16]. Cdc42 (P 
<0.05 (P=0.724), P <0.05 (P=0.032)) as a 
target for miR-137 (P <0.05 (P=0.042), P 
<0.01 (P=0.003)), reduces expression of 
miR-137 in serum of third and fourth stage 
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of disease and eventually leads to disease 
progress.  
The findings showed that miR-372 
expression in ovarian carcinoma was 
significantly less than normal ovarian tissue 
and benign tumors. That excessive 
expression of miR-372 has an inhibitory 
effect on cell proliferation and causes 
apoptosis. Therefore, miR-372 plays an 
important role in inhibiting ovarian tumor 
growth and is a significant target in the 
treatment of ovarian cancer. The high 
expression level of ATAD2 (ATPase 
family, AAA domain containing 2) was 
correlated with malignancy in ovarian 
carcinoma. 
Decreased ATAD2 gene expression inhibits 
cell proliferation and metastasis in ovarian 
cancer [17]. In the present study, miR-372 
expression was significantly increased (P 
<0.05, (0.022)) in serum of stage IV 
disease, which resulted in increased 
metastasis. MiR-372 induces metastasis by 
inhibiting fgf-9 gene expression (P <0.05 (P 
= 0.024)). 
Steroid receptor coactivator 3 (SRC3) is a 
target gene for miR-137 and miR-137 
inhibits cancer cell proliferation in NSCLC 
by affecting part of that gene. Numerous 
studies have shown that in lung cancer cells, 
miR-137 expression significantly 
suppresses the cell cycle at G1 stage and 
also decreases the growth of cancer cells by 
decreasing the expression of CDC42 and 
CDK6 genes [18]. In the present study, 
miR-137 expression (P <0.05  (P=0.042), P 
<0.01 (P=0.003)) is reduced in the third and 
fourth stages of cancer, which increases the 
expression of cdc42 gene   (P <0.05 
(P=0.724), P <0.05 (P=0.032)) and 
proliferation of lung cancer cells and 
eventually progresses to the disease. 
The profile of five miRNA expressions, 
including miR-21, miR-143, miR-155, miR-
210 and miR-372 in bronchoalveolar 
samples from people with NSCLC and 
control group and showed that these 
miRNAs play a role in tumorigenesis and 
growth. Therefore, using the evaluation of 
the expression profile of these five miRNAs 
in bronchoalveolar and sputum fluids, non-
small cell lung cancer can be detected in a 
timely manner [19]. According to the results 
of this study, the expression of miR-372 in 
the fourth stage of the disease and in 
patients with metastatic lung cancer was 
significantly increased (P <0.05(P=0.022)). 
MiR-372 binds directly to fgf-9 3′UTR (P 
<0.05 (P=0.024)) and thus leads to 
decreased fgf-9 gene expression and 
increased metastasis. 
MiR-137 disrupts the spread and migration 
of breast cancer cells by targeting the 
expression of an estrogen-related receptor 
alpha (ERRα) nuclear receptor. In the 
present study, a significant reduction P 
<0.01 (P=0.003) in the expression of miR-
137 in the fourth stage of the disease caused 
a significant increase in the expression of 
the cdc42 gene P <0.05 (P=0.032) and, as a 
result, increased metastasis [20].  
Exogenous expression of miR-372 reduced 
expression of p62 and increased the 
migration and mobility of squamous cancer 
cells in the head and neck [21]. The A549 
cells of the lung adenocarcinoma, which 
expressed excess miR-372, were faster and 
were expanded with a high percentage of 
cells in the S-cycle of the cell, and their 
ability to migrate and attack extracellular 
matrix increases [22]. In the present study, 
expression of miR-372 in the fourth stage of 
lung cancer is significantly increased (P 
<0.05(P=0.022)).  
Consequently, suppresses the expression of 
the fgf-9 gene (P <0.05 (P=0.024)) and 
promotes disease and metastasis. 
The ability of invasive lung cancer cells to 
be significantly increased by three miRNAs 
including hsa-miR-137, hsa-miR-182 and 
hsa-miR-372. They also showed that five 
miRNAs including hsa-let-7a, hsa-miR-221, 
hsa-miR-137, hsa-miR-182 and hsa-miR-
372 were linked to the survival and 
recurrence of cancer in patients with 
NSCLC [23]. Based on the results of our 
study, the expression of miR-137 
expression in the third and fourth stage of 
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the disease was significantly decreased (P 
<0.05 (P=0.042), P <0.01 (P=0.003)) and 
the expression of miR-372 (P 
<0.05(P=0.022)) in the fourth stage of the 
disease increases significantly and enhances 
the process of metastasis. 
In the present study, the results showed that 
in the third stage, miR-137 expression P 
<0.01 (P=0.003) was decreased and this 
level is increased in the fourth stage, which 
increases the expression of the cdc42 gene P 
<0.05 (P=0.032) and cell proliferation. This 
process can lead to disease progression. 
Also, miR-372 (P <0.05(P=0.022)) directly 
attaches to fgf-9 3'UTR (P <0.05 (P=0.024)) 
and thus reduces the expression of fgf-9. 
The expression of miR-372 increases the 
proliferation and invasion of lung cancer 
cells by inhibiting fgf-9. Therefore, it may 
be possible to check the expression of miR-
372 and the fgf-9 gene to predict the 
metastasis of lung cancer. Demographic 
data of patients showed a significant 
relationship between sex and smoking with 
lung cancer. There is also no significant 
relationship between the incidence of lung 
cancer among family members and the 
incidence of lung cancer. Considering the 
fact that in the present study, 46% of 
patients are aged between 61 and 70, it is 
concluded that the disease develops more 
often in the aging period. 
 
5. Conclusion 
     Based on the present study, with regard 
to the benefits of serum, including access 
and easy use of it, as well as the benefits of 
miRNAs, which includes stability and easy 
detection of serum, it is suggested that 
miRNAs in the serum should be used for 
early diagnosis and screening of lung 
cancer. This study’s data also showed that 
in the stage of metastasis, expression of 
miR-372, miR137, fgf-9 gene and cdc42 
gene was significantly changed (P <0.05) 
and it is likely that they can be a good 
candidate to check whether the treatment 
has been effective or if the tumor's tissue 
towards metastasis is in progress. To prove 
this, research needs to be done on a larger 
number of samples. 
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